Bruce B. Bank, MD

Articles

Unmet Needs and Future Directions in CLL

June 2nd 2022

Drs Bishop and Bank close by outlining remaining unmet needs in CLL, emerging regimens, and hopes for the future of care.

Key Takeaways and Clinical Implications

Michael R. Bishop, MD;Bruce B. Bank, MD

June 2nd 2022

Michael R. Bishop, MD, and Bruce B. Bank, MD, summarize key takeaways from the ELEVATE-RR study and discuss the clinical implications of using BTK inhibitors in patients with CLL.

ELEVATE-RR: Safety Data

Michael R. Bishop, MD;Bruce B. Bank, MD

June 2nd 2022

Drs Bishop and Bank discuss ELEVATE-RR safety data.

ELEVATE-RR: Efficacy Data

Michael R. Bishop, MD;Bruce B. Bank, MD

May 24th 2022

Experts discuss efficacy data from the ELEVATE-RR trial on the Bruton tyrosine kinase inhibitors acalabrutinib vs ibrutinib.

Patient Characteristics in ELEVATE-RR

Michael R. Bishop, MD;Bruce B. Bank, MD

May 24th 2022

Dr Bishop comments on the characteristics of the patients with CLL who were enrolled in the ELEVATE-RR trial.

ELEVATE-RR Study Overview

Michael R. Bishop, MD;Bruce B. Bank, MD

May 16th 2022

Dr Bishop reviews the ELEVATE-RR trial enrollment strategy.

Introduction and CLL Background

Michael R. Bishop, MD;Bruce B. Bank, MD

May 16th 2022

Michael R. Bishop, MD, introduces the 2021 Journal of Clinical Oncology publication, “Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial” and invites Bruce B. Bank, MD, to comment on the typical patients with chronic lymphocytic leukemia (CLL) he sees in his clinical practice.